Drug intelligence / Profile preview

GM100 series

Development stage: Preclinical
Lead developer: GlycoMantra
Modality: Small Molecules

Overview

The GM100 series are galectin-3 antagonists developed by GlycoMantra, Inc. These compounds are being explored for various therapeutic indications, including **metastatic prostate carcinoma** and **triple negative breast cancer**. Galectin-3 is a protein involved in various biological processes, and inhibiting it may have therapeutic benefits in diseases like cancer and fibrosis.

Other names: Galectin-3 antagonistsGalectin3 antagonistsGalectin 3 antagonists

Targets

LGALS3 (Galectin-3)

Beyond the preview

Go deeper on GM100 series.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM100 series.

Explore the full profile